A risk adjustment approach to estimating the burden of skin disease in the United States

Lim, Henry W.; Collins, Scott; Resneck, Jack S.; Bolognia, Jean L.; Hodge, Julie A.; Rohrer, Thomas A.; VanBeek, Marta; Margolis, David J.; Sober, Arthur J.; Weinstock, Martin A.; Nerenz, David R.; Begolka, Wendy Smith; Moyano, José V.

doi:10.1016/j.jaad.2017.08.060

Cited by 21 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HRQoL scores (n = 245) were worse in advanced-stage disease (IIB-IV) vs. early-stage (IA-IIA). Eighty-five percent of respondents reported that their treatment made their disease seem more manageable, but 61% felt financially burdened (19), which was verified recently by risk adjustment showing that CTCL consistently ranked in the top 3 positions of financial burden due to skin diseases (36). Wright et al (21) confirmed these data, showing that advanced-stage disease and more severe pruritus were associated with poorer HRQoL in CTCL.…”

Section: Health-related Quality Of Life Questionnaire Outcomes In Cutmentioning

confidence: 78%

Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future

Jonak

Porkert²,

Oerlemans³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

Previous studies have reported that primary cutaneous lymphomas profoundly influence patients' health-related quality of life (HRQoL). However, assessment of this psycho-social concept is not common in routine patient care unless required within clinical trials. The aim of this review is to provide a comprehensive overview of HRQoL measures and outcomes in cutaneous lymphomas in order to inform clinicians. Advanced-stage cutaneous lymphomas were found to be associated with worse HRQoL than early-stage disease. Specifically, progression of the disease, age, sex, psychosocial issues, educational level and therapy were related to the extent of impairment of HRQoL. Treatment response was linked to improved HRQoL, but notably ameliorated HRQoL scores were also reported despite objective disease response. However, the variety of instruments applied to measure HRQoL in cutaneous lymphomas makes it difficult to compare data directly. In conclusion, speciality-specific HRQoL instruments were superior to generic ones, which probably failed to recognize small, but relevant, changes, demonstrating the need for a disease-specific tool.

show abstract

Section: Health-related Quality Of Life Questionnaire Outcomes In Cutmentioning

confidence: 78%

Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future

Jonak

Porkert²,

Oerlemans³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…The individual annual cost of CTCL has been previously estimated as $3948. 5 In this context, our estimate of $73 889 over the lifetime of an individual patient would have to correspond to an average life expectancy of 18Á7 years after CTCL diagnosis. In fact, the stage-weighted CTCL-specific life expectancy in our patient population was 18Á7 years.…”

Section: Discussionmentioning

confidence: 99%

“…perspective, CTCL has also been associated with a higher annual incremental cost than any other skin disease, 3,5 although the long-term economic burden of CTCL to patients and society at large remains to be quantified. Despite the potential for this condition to compromise various aspects of patient well-being, few studies have investigated the impact of CTCL on overall health-related quality of life (QoL).…”

mentioning

confidence: 99%

Health‐related quality of life and economic implications of cutaneous T‐cell lymphoma

et al. 2019

View full text Add to dashboard Cite

Summary Background Cutaneous T‐cell lymphoma (CTCL) has been associated with considerable physical, psychological and financial burden. However, its impact on health‐related quality of life (QoL) and economic costs are not well studied. Objectives To measure the QoL impact and financial burden of CTCL. Methods A cross‐sectional survey of 67 patients with CTCL was conducted using the Ontario Health Utilities Index Mark 3 (HUI3) questionnaire. Normative population data (n = 3310) were obtained from the 2002–2003 Joint Canada/United States Survey of Health. Economic cost was estimated using quality‐adjusted life‐year (QALY) loss derived from HUI3 scores. Results Patients with CTCL had significantly lower aggregate HUI3 scores than the general population (0·68 vs. 0·87, P < 0·001). Multivariable regression analysis adjusting for demographics and comorbidities showed CTCL was associated with significantly poorer performance overall (–0·13, 95% CI –0·21 to –0·06, P < 0·001) and in domains of speech (–0·03, 95% CI –0·05 to –0·01, P = 0·01), ambulation (–0·04, 95% CI –0·08 to 0·00, P = 0·03), emotion (–0·07, 95% CI –0·12 to –0·02, P = 0·01), and pain (–0·07, 95% CI –0·13 to –0·01, P = 0·03). These health utility decrements yielded an average loss of 1·48 QALYs per patient. Using a $50 000 per QALY willingness‐to‐pay threshold, CTCL was associated with an individual lifetime burden of $73 889 and U.S. societal burden of $2·86 billion. Conclusions These findings suggest CTCL has a pervasive impact on QoL, comparable with debilitating conditions such as end‐stage renal disease. The substantial economic burden of CTCL underscores the potential societal benefit of prompt diagnosis and effective management. What's already known about this topic? Cutaneous T‐cell lymphoma is associated with physical, psychological and financial burden. What does this study add? The overall quality‐of‐life impact of cutaneous T‐cell lymphoma has not previously been measured using a generic health utility instrument. In this study, we compare the overall quality‐of‐life burden of patients with cutaneous T‐cell lymphoma with that of other populations and calculate the economic burden of the disease.

show abstract

“…The prevalence of atopic dermatitis in this study, roughly 5%, is lower than in other studies, and the cost of over-the-counter products was not included. More recently, using different methods, Lim et al [107,108] showed that the direct US healthcare costs of atopic dermatitis in 2013 were between 252 USD million and 314 USD million.…”

Section: Direct Healthcare Costsmentioning

confidence: 99%

Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

Dierick

Molen

Blok

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

201

157

View full text Add to dashboard Cite

Introduction: Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately 20% of the global population. Few studies describe the burden of the totality of these diseases and only a handful studies provide a comprehensive overview of the socioeconomic impact of these diseases. Areas covered: For this narrative review, we searched Pubmed using selected keywords and inspected relevant references using a snowballing process. We provide an overview of the socioeconomic burden of allergic diseases (in particular, asthma, allergic rhinitis, atopic dermatitis, and food allergy). The focus of this review is on their epidemiology (incidence, prevalence), burden (disability-adjusted life years, quality of life), and direct and indirect costs (absenteeism and presenteeism). We have put special emphasis on differences between countries. Expert commentary: Both the prevalence and the burden of allergic diseases are considerable with prevalence varying between 1% and 20%. We identified a plethora of studies on asthma, but studies were generally difficult to compare due to the heterogeneity in measures used. There were only few studies on the burden of food allergy; therefore, more studies on this allergy are required. For future studies, we recommend standardizing epidemiologic, socioeconomic impact, and quality of life measures of allergic diseases.

show abstract

A risk adjustment approach to estimating the burden of skin disease in the United States

Cited by 21 publications

References 11 publications

Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future

Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future

Health‐related quality of life and economic implications of cutaneous T‐cell lymphoma

Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

Contact Info

Product

Resources

About